Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Natura Bisse International S.A.
WARNING LETTER
•Natura Bisse International S.A.•January 29, 2016

Natura Bisse International S.A. – FDA Warning Letter, Jan 29, 2016

Record Details

The FDA issued a Warning Letter to Natura Bisse International S.A. following an inspection from January 25-29, 2016, at their Barcelona, Spain facility, identifying significant CGMP violations for finished pharmaceuticals, rendering their drug products adulterated.

Key violations include: 1. **Failure to test drug products for identity and strength prior to release (21 CFR 211.165(a))**: Specifically, OTC drug products were not tested. This was a repeat violation from a 2013 inspection. The FDA requires a release testing program, including SOPs, retroactive assessment of in-expiry batches for the U.S. market, and copies of quality agreements with contract laboratories. 2. **Failure to support expiration dates with appropriate stability testing (21 CFR 211.137(a))**: No stability testing program was implemented, and a 2015 recall due to product separation indicated instability. This was also a repeat violation from 2013. The FDA requires a stability testing program with stability-indicating methods, acceptance criteria, and retroactive assessment of in-expiry batches for the U.S. market. 3. **Failure to follow required laboratory control mechanisms (21 CFR 211.160(a))**: Laboratory log sheets for microbiology, physico-chemical, and organoleptic tests lacked appropriate controls. The FDA requires

Company
Natura Bisse International S.A.
Inspection date
January 29, 2016
Product type
Drugs
Office
Center for Drug Evaluation and Research
Person
  • Francis Godwin (Director)
View Company Profile

ID · 09a4624b-cf23-4da4-a426-a8478ad39d18

Violation Codes9
21 U.S.C. 351(a)(2)(B)21 CFR 21021 CFR 21121 CFR 211.165(a)21 CFR 211.137(a)21 CFR 211.160(a)FD&C Act 501(a)(2)(B)FD&C Act 801(a)(3)21 U.S.C. 381(a)(3)

Full citation text and observation details available on the Dashboard.

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Natura Bisse International S.A.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.